SUPPLEMENT

Q4 2023 — Non-GAAP reconciliations

Q4 2023PDF · 21 pages298 KB
DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
AND SUPPLEMENTAL FORWARD-LOOKING INFORMATION
THREE-MONTH PERIODS AND YEARS ENDED DECEMBER 31, 2023 AND DECEMBER 31, 2022

-- 1 of 21 --

TABLE OF CONTENTS
Page
1 Sales (Decline) Growth by Segment, Core Sales (Decline) Growth by Segment and Base Business Core Sales (Decline) Growth by Segment
2 Forecasted Core Sales (Decline) Growth and Adjusted Operating Profit Margin
3 Segment Sales, Operating Profit and Adjusted Operating Profit
4 Net Earnings From Continuing Operations, Operating Profit, Adjusted EBITDA, Net Earnings from Continuing Operations Margin, Operating
Profit Margin and Adjusted EBITDA Margin
8 Other Non-GAAP Adjusted P&L Measures
14 Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
15 Year-Over-Year Core Operating Margin Changes from Continuing Operations
16 Cash Flow from Continuing Operations, Free Cash Flow from Continuing Operations, Operating Cash Flow from Continuing Operations to Net
Earnings from Continuing Operations Ratio and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations
Conversion Ratio
17 Statement Regarding Non-GAAP Measures
FORWARD-LOOKING STATEMENTS DISCLOSURE
Statements in this document that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-
looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ
materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include,
among other things, potential future, adverse impacts on our business, results of operations and financial condition related to the COVID-19 pandemic, the impact of our debt obligations on our
operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets, uncertainties relating to national laws or policies, including laws or policies
to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully
market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and
regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof,
our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic
investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire (including the acquisition of Abcam plc) and achieve the anticipated
growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related
and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy
laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes
in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental,
health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production
capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to fluctuations in the cost and availability of the
supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration
arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and
our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds,
experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts), disruptions relating to man-made and natural
disasters, pension plan and healthcare costs, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ
materially from these forward-looking statements is available in our SEC filings, including our 2022 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2023.
These forward-looking statements speak only as of the date of this document (January 29, 2024) and except to the extent required by applicable law, the Company does not assume any
obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

-- 2 of 21 --

% Change Three-Month Period Ended December 31, 2023 vs. Comparable
2022 Period
Segments
Total Company Biotechnology Life Sciences Diagnostics
Total sales decline (GAAP) (10.0) % (21.0) % (1.0) % (8.5) %
Impact of:
Acquisitions/divestitures (0.5) % — % (2.5) % — %
Currency exchange rates (1.0) % (1.5) % (0.5) % — %
Core sales decline (non-GAAP) (11.5) % (22.5) % (4.0) % (8.5) %
Impact of COVID-19 related testing, vaccines and therapeutics 7.0 % +Mid-single
digit +Up slightly +High-teens
Base business core sales (decline) growth (non-GAAP) (4.5) % -High-teens -Low-single
digit +High-single
digit
% Change Year Ended December 31, 2023 vs. Comparable 2022 Period
Segments
Total Company Biotechnology Life Sciences Diagnostics
Total sales (decline) growth (GAAP) (10.5) % (18.0) % 1.5 % (11.5) %
Impact of:
Acquisitions/divestitures (0.5) % — % (1.5) % — %
Currency exchange rates 1.0 % — % 1.0 % 1.0 %
Core sales (decline) growth (non-GAAP) (10.0) % (18.0) % 1.0 % (10.5) %
Impact of COVID-19 related testing, vaccines and therapeutics 9.5 % +High-single
digit +Low-single
digit +High-teens
Base business core sales (decline) growth (non-GAAP) (0.5) % -Low-double
digit +Low-single
digit +High-single
digit
Note: We expect overall demand for the Company’s COVID-19 related products to continue moderating as the pandemic has evolved toward endemic status. We believe certain demand for the
Company’s products that support COVID-19 related vaccines and therapeutics and COVID-19 testing (which includes solutions that test for COVID-19 and other respiratory illnesses
simultaneously) will continue, though that demand will likely be uncertain and will vary from period to period. At the beginning of 2022, the Company believed that on a relative basis, the level of
ongoing demand for products supporting COVID-19 testing would be subject to more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and
therapeutics, due in part to expected COVID-19 case levels, vaccination rates and use of therapies. However, as a result of lower vaccination rates and the spread of less severe variants of the
virus, 2022 demand for the Company’s products supporting COVID-19 related vaccines and therapeutics fluctuated and declined more than anticipated at the beginning of the year. Therefore,
beginning with the first quarter of 2023, we have revised the definition of “base business core sales growth” on a basis that not only excludes revenues related to COVID-19 testing but also
excludes revenues from products that support COVID-19 related vaccines and therapeutics. We believe this adjusted definition of “base business core sales growth” provides more useful
information to investors by facilitating period-to-period comparisons of our financial performance and identifying underlying growth trends in the Company’s business that otherwise may be
obscured by fluctuations in demand for COVID-19 related products.
DANAHER CORPORATION
Sales (Decline) Growth by Segment, Core Sales (Decline) Growth by Segment and Base Business Core Sales (Decline) Growth by Segment
1

-- 3 of 21 --

The Company provides forecasted sales only on a non-GAAP basis because of the difficulty in estimating the other components of GAAP revenue, such as
currency translation, acquisitions and divested product lines. Beginning with the first quarter of 2024 the Company will continue to provide guidance for core
revenue growth, but will no longer provide guidance for, or report base business core revenue as the pandemic has transitioned to an endemic state. Additionally,
we do not reconcile forecasted adjusted operating profit margin (or components thereof) to the comparable GAAP measures because of the difficulty in estimating
the other components (in addition to items identified in the prior sentence) such as investment gains and losses, impairments and separation costs, which would be
reflected in any forecasted GAAP operating profit.
% Change Three-Month
Period Ending March 29,
2024 vs. Comparable
2023 Period
% Change Year Ending
December 31, 2024 vs.
Comparable 2023
Period
Core sales decline (non-GAAP) -High-single digit -Low-single digit
Three-Month Period
Ending March 29, 2024
Adjusted operating profit margin (non-GAAP) ~28.0 %
Year Ending December
31, 2024
Year-over-year change in adjusted operating profit margin (non-GAAP) ~+0.5%
DANAHER CORPORATION
Forecasted Core Sales Decline and Adjusted Operating Profit Margin
2

-- 4 of 21 --

Sales (GAAP)
Biotechnology $ 1,759 $ 2,223 $ 7,172 $ 8,758
Life Sciences 1,930 1,946 7,141 7,036
Diagnostics 2,716 2,965 9,577 10,849
Total Company $ 6,405 $ 7,134 $ 23,890 $ 26,643
Operating Profit (GAAP)
Biotechnology $ 416 $ 693 $ 1,909 $ 3,008
Life Sciences 235 392 1,209 1,414
Diagnostics 766 989 2,406 3,436
Other (80) (77) (322) (322)
Total Company $ 1,337 $ 1,997 $ 5,202 $ 7,536
Amortization of Intangible Assets (GAAP)
Biotechnology $ 215 $ 196 $ 864 $ 812
Life Sciences 116 104 429 419
Diagnostics 49 52 198 203
Total Company $ 380 $ 352 $ 1,491 $ 1,434
Other Operating Profit Adjustments 1
Biotechnology $ 12 $ — $ 54 $ 14
Life Sciences 85 — 85 24
Diagnostics 23 — 23 3
Other — — — 1
Total Company $ 120 $ — $ 162 $ 42
Adjusted Operating Profit (non-GAAP) 2
Biotechnology $ 643 $ 889 $ 2,827 $ 3,834
Life Sciences 436 496 1,723 1,857
Diagnostics 838 1,041 2,627 3,642
Other (80) (77) (322) (321)
Total Company $ 1,837 $ 2,349 $ 6,855 $ 9,012
Three-Month Period Ended Year Ended
December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
2 Adjusted Operating Profit (non-GAAP) is defined as operating profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined).
DANAHER CORPORATION
Segment Sales, Operating Profit and Adjusted Operating Profit
($ in millions)
3

-- 5 of 21 --

Three-Month Period Ended December 31, 2023
Biotechnology Life Sciences Diagnostics Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 1,121
Interest, Net (32)
Other Nonoperating (Income) Expense 137
Income Taxes 111
Operating Profit (GAAP) $ 416 $ 235 $ 766 $ (80) $ 1,337
Other Operating Profit Adjustments 1 12 85 23 — 120
Depreciation 43 37 97 1 178
Amortization of Intangible Assets 215 116 49 — 380
Adjusted EBITDA (Non-GAAP) $ 686 $ 473 $ 935 $ (79) $ 2,015
Interest, Net 32
Other Nonoperating Income (Expense) (137)
Income Taxes (111)
Other Operating Profit Adjustments 1 (120)
Depreciation (178)
Amortization of Intangible Assets (380)
Net Earnings from Continuing Operations (GAAP) $ 1,121
Sales (GAAP) $ 1,759 $ 1,930 $ 2,716 $ 6,405
Net Earnings from Continuing Operations Margin (GAAP) 17.5 %
Operating Profit Margin (GAAP) 23.6 % 12.2 % 28.2 % 20.9 %
Adjusted EBITDA Margin (Non-GAAP) 3 39.0 % 24.5 % 34.4 % 31.5 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP).
DANAHER CORPORATION
Net Earnings From Continuing Operations, Operating Profit, Adjusted EBITDA, Net Earnings From Continuing Operations Margin, Operating Profit
Margin and Adjusted EBITDA Margin
($ in millions)
4

-- 6 of 21 --

Three-Month Period Ended December 31, 2022
Biotechnology Life Sciences Diagnostics Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 2,012
Interest, Net 33
Other Nonoperating (Income) Expense 69
Income Taxes (117)
Operating Profit (GAAP) $ 693 $ 392 $ 989 $ (77) $ 1,997
Other Operating Profit Adjustments 1 — — — — —
Depreciation 63 28 97 4 192
Amortization of Intangible Assets 196 104 52 — 352
Adjusted EBITDA (Non-GAAP) $ 952 $ 524 $ 1,138 $ (73) $ 2,541
Interest, Net (33)
Other Nonoperating Income (Expense) (69)
Income Taxes 117
Other Operating Profit Adjustments 1 —
Depreciation (192)
Amortization of Intangible Assets (352)
Net Earnings from Continuing Operations (GAAP) $ 2,012
Sales (GAAP) $ 2,223 $ 1,946 $ 2,965 $ 7,134
Net Earnings from Continuing Operations Margin (GAAP) 28.2 %
Operating Profit Margin (GAAP) 31.2 % 20.1 % 33.4 % 28.0 %
Adjusted EBITDA Margin (Non-GAAP) 3 42.8 % 26.9 % 38.4 % 35.6 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP).
DANAHER CORPORATION
Net Earnings From Continuing Operations, Operating Profit, Adjusted EBITDA, Net Earnings From Continuing Operations Margin, Operating Profit
Margin and Adjusted EBITDA Margin
($ in millions)
5

-- 7 of 21 --

Year Ended December 31, 2023
Biotechnology Life Sciences Diagnostics Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 4,221
Interest, Net (17)
Other Nonoperating (Income) Expense 175
Income Taxes 823
Operating Profit (GAAP) $ 1,909 $ 1,209 $ 2,406 $ (322) $ 5,202
Other Operating Profit Adjustments 1 54 85 23 — 162
Depreciation 162 129 379 5 675
Amortization of Intangible Assets 864 429 198 — 1,491
Adjusted EBITDA (Non-GAAP) $ 2,989 $ 1,852 $ 3,006 $ (317) $ 7,530
Interest, Net 17
Other Nonoperating Income (Expense) (175)
Income Taxes (823)
Other Operating Profit Adjustments 1 (162)
Depreciation (675)
Amortization of Intangible Assets (1,491)
Net Earnings from Continuing Operations (GAAP) $ 4,221
Sales (GAAP) $ 7,172 $ 7,141 $ 9,577 $ 23,890
Net Earnings from Continuing Operations Margin (GAAP) 17.7 %
Operating Profit Margin (GAAP) 26.6 % 16.9 % 25.1 % 21.8 %
Adjusted EBITDA Margin (Non-GAAP) 3 41.7 % 25.9 % 31.4 % 31.5 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP).
DANAHER CORPORATION
Net Earnings From Continuing Operations, Operating Profit, Adjusted EBITDA, Net Earnings From Continuing Operations Margin, Operating Profit
Margin and Adjusted EBITDA Margin
($ in millions)
6

-- 8 of 21 --

Year Ended December 31, 2022
Biotechnology Life Sciences Diagnostics Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 6,328
Interest, Net 163
Other Nonoperating (Income) Expense 227
Income Taxes 818
Operating Profit (GAAP) $ 3,008 $ 1,414 $ 3,436 $ (322) $ 7,536
Other Operating Profit Adjustments 1 14 24 3 1 42
Depreciation 190 112 387 9 698
Amortization of Intangible Assets 812 419 203 — 1,434
Adjusted EBITDA (Non-GAAP) $ 4,024 $ 1,969 $ 4,029 $ (312) $ 9,710
Interest, Net (163)
Other Nonoperating Income (Expense) (227)
Income Taxes (818)
Other Operating Profit Adjustments 1 (42)
Depreciation (698)
Amortization of Intangible Assets (1,434)
Net Earnings from Continuing Operations (GAAP) $ 6,328
Sales (GAAP) $ 8,758 $ 7,036 $ 10,849 $ 26,643
Net Earnings from Continuing Operations Margin (GAAP) 23.8 %
Operating Profit Margin (GAAP) 34.3 % 20.1 % 31.7 % 28.3 %
Adjusted EBITDA Margin (Non-GAAP) 3 45.9 % 28.0 % 37.1 % 36.4 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP).
DANAHER CORPORATION
Net Earnings From Continuing Operations, Operating Profit, Adjusted EBITDA, Net Earnings From Continuing Operations Margin, Operating Profit
Margin and Adjusted EBITDA Margin
($ in millions)
7

-- 9 of 21 --

Three-Month Period Ended December 31, 2023
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before
income taxes Income taxes
Net earnings
from continuing
operations for
calculation of
diluted earnings
per common
share
Diluted net
earnings per
common
share from
continuing
operations 4
Reported (GAAP) $ 6,405 $ (2,626) 59.0 % $ 1,337 20.9 % $ 1,232 $ (111) $ 1,121 J $ 1.50
Amortization of acquisition-related
intangible assets A — — — 380 5.9 380 380 0.51
Fair value net (gains) losses on
investments B — — — — — 139 139 0.19
Impairments and other charges C — — — 35 0.5 35 35 0.05
Acquisition-related items D — 8 0.1 95 1.5 95 95 0.13
Litigation gains E — — — (10) (0.2) (10) (10) (0.01)
Tax effect of the above adjustments G (131) (131) (0.18)
Discrete tax adjustments H (71) (71) (0.10)
Rounding — — — — 0.1 — — — —
Adjusted (Non-GAAP) $ 6,405 $ (2,618) 59.1 % $ 1,837 28.7 % $ 1,871 $ (313) $ 1,558 $ 2.09
Three-Month Period Ended December 31, 2023
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research
and
development
expenses
Research
and
development
expenses as
a % of sales
Nonoperating
income
(expense),
net
(excluding
interest)
Interest
income
(expense),
net
Reported (GAAP) $ 6,405 $ (2,035) (31.8) % $ (407) (6.4) % $ (137) $ 32
Amortization of acquisition-related
intangible assets A — 380 5.9 — — — —
Fair value net (gains) losses on
investments B — — — — — 139 —
Impairments and other charges C — 35 0.5 — — — —
Acquisition-related items D — 87 1.4 — — — —
Litigation gains E — (10) (0.2) — — — —
Rounding — — 0.1 — — — —
Adjusted (Non-GAAP) $ 6,405 $ (1,543) (24.1) % $ (407) (6.4) % $ 2 $ 32
4 Net earnings per diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
8

-- 10 of 21 --

Three-Month Period Ended December 31, 2022
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before
income taxes Income taxes
Net earnings
from continuing
operations for
calculation of
diluted earnings
per common
share
Diluted net
earnings per
common
share from
continuing
operations 5
Reported (GAAP) $ 7,134 $ (2,908) 59.2 % $ 1,997 28.0 % $ 1,895 $ 117 $ 2,012 J $ 2.70
Amortization of acquisition-related
intangible assets A — — — 352 4.9 352 352 0.47
Fair value net (gains) losses on
investments B — — — — — 85 85 0.11
Tax effect of the above adjustments G (94) (94) (0.13)
Discrete tax adjustments H (459) (459) (0.62)
Rounding — — — — — — — 0.01
Adjusted (Non-GAAP) $ 7,134 $ (2,908) 59.2 % $ 2,349 32.9 % $ 2,332 $ (436) $ 1,896 $ 2.54
Three-Month Period Ended December 31, 2022
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research
and
development
expenses
Research
and
development
expenses as
a % of sales
Nonoperating
income
(expense),
net
(excluding
interest)
Interest
income
(expense),
net
Reported (GAAP) $ 7,134 $ (1,829) (25.6) % $ (400) (5.6) % $ (69) $ (33)
Amortization of acquisition-related
intangible assets A — 352 4.9 — — — —
Fair value (gains) losses on
investments B — — — — — 85 —
Adjusted (Non-GAAP) $ 7,134 $ (1,477) (20.7) % $ (400) (5.6) % $ 16 $ (33)
5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock for all periods presented
prior to their conversion on April 17, 2023. Net earnings per diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
9

-- 11 of 21 --

Year Ended December 31, 2023
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before
income taxes Income taxes
Net earnings
from continuing
operations for
calculation of
diluted earnings
per common
share
Diluted net
earnings per
common
share from
continuing
operations 5
Reported (GAAP) $ 23,890 $ (9,856) 58.7 % $ 5,202 21.8 % $ 5,044 $ (823) $ 4,200 J $ 5.65
Amortization of acquisition-related
intangible assets A — — — 1,491 6.2 1,491 1,491 2.00
Fair value net (gains) losses on
investments B — — — — — 182 182 0.24
Impairments and other charges C — 14 0.1 77 0.3 77 77 0.10
Acquisition-related items D — 8 — 95 0.4 95 95 0.13
Litigation gains E — — — (10) — (10) (10) (0.01)
Tax effect of the above adjustments G (354) (354) (0.47)
Discrete tax adjustments H (47) (47) (0.06)
MCPS "as if converted" I — — — — — — — 21 0.01
Rounding — — — — — — — — (0.01)
Adjusted (Non-GAAP) $ 23,890 $ (9,834) 58.8 % $ 6,855 28.7 % $ 6,879 $ (1,224) $ 5,655 $ 7.58
Year Ended December 31, 2023
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research
and
development
expenses
Research
and
development
expenses as
a % of sales
Nonoperating
income
(expense),
net
(excluding
interest)
Interest
income
(expense),
net
Reported (GAAP) $ 23,890 $ (7,329) (30.7) % $ (1,503) (6.3) % $ (175) $ 17
Amortization of acquisition-related
intangible assets A — 1,491 6.2 — — — —
Fair value net (gains) losses on
investments B — — — — — 182 —
Impairments and other charges C — 63 0.3 — — — —
Acquisition-related items D — 87 0.4 — — — —
Litigation gains E — (10) — — — — —
Rounding — — (0.1) — — — —
Adjusted (Non-GAAP) $ 23,890 $ (5,698) (23.9) % $ (1,503) (6.3) % $ 7 $ 17
5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock for all periods presented
prior to their conversion on April 17, 2023. Net earnings per diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
10

-- 12 of 21 --

Year Ended December 31, 2022
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before
income taxes Income taxes
Net earnings
from continuing
operations for
calculation of
diluted earnings
per common
share
Diluted net
earnings per
common
share from
continuing
operations 5
Reported (GAAP) $ 26,643 $ (10,455) 60.8 % $ 7,536 28.3 % $ 7,146 $ (818) $ 6,242 J $ 8.47
Amortization of acquisition-related
intangible assets A — — — 1,434 5.4 1,434 1,434 1.92
Fair value net (gains) losses on
investments B — — — — — 271 271 0.36
Impairments and other charges C — 18 0.1 42 0.2 42 42 0.06
Loss on partial settlement of a defined
benefit plan F — — — — — 10 10 0.01
Tax effect of the above adjustments G (345) (345) (0.46)
Discrete tax adjustments H (500) (500) (0.67)
MCPS "as if converted" I — — — — — — — 86 0.02
Rounding — — (0.1) — (0.1) — — — —
Adjusted (Non-GAAP) $ 26,643 $ (10,437) 60.8 % $ 9,012 33.8 % $ 8,903 $ (1,663) $ 7,240 $ 9.71
Year Ended December 31, 2022
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research
and
development
expenses
Research
and
development
expenses as
a % of sales
Nonoperating
income
(expense) net
(excluding
interest)
Interest
income
(expense),
net
Reported (GAAP) $ 26,643 $ (7,124) (26.7) % $ (1,528) (5.7) % $ (227) $ (163)
Amortization of acquisition-related
intangible assets A — 1,434 5.4 — — — —
Fair value net (gains) losses on
investments B — — — — — 271 —
Impairments and other charges C — 24 0.1 — — — —
Loss on partial settlement of a defined
benefit plan F — — — — — 10 —
Rounding — — (0.1) — — — —
Adjusted (Non-GAAP) $ 26,643 $ (5,666) (21.3) % $ (1,528) (5.7) % $ 54 $ (163)
5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock for all periods
presented. Net earnings per diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
11

-- 13 of 21 --

A Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected
in the amortization line item above):
Three-Month Period Ended Year Ended
December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022
Pretax $ 380 $ 352 $ 1,491 $ 1,434
After-tax 317 286 1,226 1,166
B Net (gains) losses, including impairments, on the Company's equity and limited partnership investments recorded in the following historical periods ($ in
millions) (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above):
Three-Month Period Ended Year Ended
December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022
Pretax $ 139 $ 85 $ 182 $ 271
After-tax 98 57 130 198
C Impairment charge related to technology-based intangible assets in the Diagnostics segment recorded in the three-month period and year ended
December 31, 2023 ($23 million pretax as reported in this line, $18 million after-tax) and technology-based intangible assets and other assets in the
Biotechnology segment recorded in the three-month period and year ended December 31, 2023 ($12 million and $54 million pretax as reported in this line
item, $8 million and $40 million after-tax, respectively). In the year ended December 31, 2022 charges incurred primarily related to impairments of
accounts receivable and inventory as well as accruals for contractual obligations in Russia ($42 million pretax as reported in this line item, $39 million
after-tax).
D Transaction costs deemed significant, settlement of pre-acquisition share-based payment awards and fair value adjustments to inventory in each case
related to the acquisition of Abcam in the three-month period and year ended December 31, 2023 ($95 million pretax as reported in this line item, $75
million after-tax). The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the
Company’s larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given
period.
E Gain related to settlement of litigation in the Life Sciences segment recorded in the three-month period and year ended December 31, 2023 ($10 million
pretax as reported in this line, $8 million after-tax).
F Loss on a partial settlement of a defined benefit plan as a result of the transfer of a portion of the Company’s non-U.S. pension liabilities related to one
defined benefit plan to a third-party in the year ended December 31, 2022 ($10 million pretax as reported in this line item, $9 million after-tax).
G This line item reflects the aggregate tax effect of all non-tax adjustments reflected in the preceding line items of the table. In addition, the footnotes above
indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall
estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires
application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.
The MCPS dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends.
H Discrete tax adjustments and other tax-related adjustments for the three-month period ended December 31, 2023, include the impact of net discrete tax
benefits of $71 million due principally to net deferred tax benefits resulting from changes in estimates related to prior year tax filing positions and the
release of reserves for uncertain tax positions due to the expiration of statutes of limitation, net of charges related to changes in estimates associated with
prior period uncertain tax positions. Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2023 include the impact
of net discrete tax benefits of $47 million due principally to net discrete tax benefits from changes in estimates related to prior year tax filing positions, the
release of reserves for uncertain tax positions due to the expiration of statutes of limitation and excess tax benefits from stock-based compensation, net of
charges related to tax costs related to the separation of Veralto Corporation, tax costs from legal and operational actions undertaken to realign certain of
its businesses and changes in estimates associated with prior period uncertain tax positions. Discrete tax adjustments for both the three-month period
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
12

-- 14 of 21 --

and year ended December 31, 2022, include the impact of net discrete tax benefits of $459 million and $500 million, respectively, due principally to net
deferred tax benefits resulting from legal and operational actions undertaken to realign certain of Danaher’s businesses, as well as excess tax benefits
from stock-based compensation, the release of reserves for uncertain tax positions due to the expiration of statutes of limitation and audit settlements and
changes in estimates related to prior year tax filing positions, net of changes in estimates associated with prior period uncertain tax positions. The
Company anticipates excess tax benefits from stock compensation of approximately $7 million per quarter and therefore excludes benefits in excess of
this amount in the calculation of adjusted diluted net earnings from continuing operations per common share.
I In March 2019, the Company issued $1.65 billion in aggregate liquidation preference of 4.75% MCPS Series A. In May 2020, the Company issued $1.72
billion in aggregate liquidation preference of 5.0% MCPS Series B. Dividends on the MCPS Series A and Series B were payable on a cumulative basis at
an annual rate of 4.75% and 5.0%, respectively, on the liquidation preference of $1,000 per share. Each share of MCPS Series A converted on April 15,
2022 into 6.6632 shares of Danaher’s common stock. Each share of MCPS Series B converted on April 17, 2023 into 5.0175 shares of Danaher’s
common stock. For the calculation of net earnings per common share from continuing operations, the impact of the dilutive MCPS is calculated under the
“if-converted” method and the related MCPS dividends are excluded. For the purposes of calculating adjusted earnings per common share from
continuing operations, the Company has excluded the paid MCPS cash dividends and assumed the “if-converted” method of share dilution (the
incremental shares of common stock deemed outstanding applying the “if-converted” method of calculating share dilution only with respect to any MCPS
the conversion of which would be dilutive in the particular period are referred to as the “Converted Shares”) for any MCPS that were anti-dilutive for the
given period. For additional information about the impact of the MCPS on the calculation of diluted EPS, see note 6 in the Average and Adjusted Average
Common Stock and Common Equivalent Diluted Shares Outstanding table below.
J Net earnings from continuing operations for calculation of diluted earnings per common share is summarized as follows ($ in millions):
Three-Month Period Ended Year Ended
December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022
Net earnings from continuing operations $ 1,121 $ 2,012 $ 4,221 $ 6,328
MCPS dividends — (22) (21) (106)
Net earnings from continuing operations attributable to common stockholders
for Basic EPS 1,121 1,990 4,200 6,222
Adjustment for MCPS dividends for dilutive MCPS — 22 — 20
Net earnings from continuing operations attributable to common stockholders
after assumed conversions for Diluted EPS $ 1,121 $ 2,012 $ 4,200 $ 6,242
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
13

-- 15 of 21 --

Three-Month Period Ended Year Ended
December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022
Average common stock and common equivalent shares outstanding - diluted (GAAP) 6 746.1 745.7 743.1 737.1
Converted shares 7 — — 2.5 8.6
Adjusted average common stock and common equivalent shares outstanding - diluted
(non-GAAP) 746.1 745.7 745.6 745.7
6 The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for the years ended December 31, 2023 and 2022, and as such, approximately 2.5 million
shares and 8.6 million shares, respectively, underlying the MCPS Series B are excluded from the calculation of diluted EPS for the periods and the related MCPS Series B dividends of $21
million and $86 million were included in the calculation of net earnings for diluted EPS for the respective periods.
The impact of the MCPS Series B calculated under the if-converted method was dilutive for the three-month period ended December 31, 2022, and as such 8.6 million shares underlying the
MCPS Series B were included in the calculation of diluted EPS in the period and the related MCPS Series B dividends of $22 million were excluded from the calculation of net earnings for
diluted EPS for the period.
The impact of the MCPS Series A calculated under the if-converted method was dilutive for the year ended December 31, 2022, and as such 3.0 million shares underlying the MCPS Series
A were included in the calculation of diluted EPS in the periods and the related MCPS Series A dividends of $20 million were excluded from the calculation of net earnings for diluted EPS for
the period.
7 The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using the actual
conversion rates for the year ended December 31, 2023 and an average 20 trading-day trailing Volume Weighted Average Price of $266.27 as of December 31, 2022.
DANAHER CORPORATION
Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
(shares in millions)
14

-- 16 of 21 --

Segments
Total Company Biotechnology Life Sciences Diagnostics
Three-Month Period Ended December 31, 2022 Operating Profit Margins from Continuing
Operations (GAAP) 28.00 % 31.20 % 20.10 % 33.40 %
Fourth quarter 2023 impact from operating profit margins of businesses that have been
owned for less than one year or were disposed of during such period and did not qualify as
discontinued operations (0.25) — (0.75) —
Fourth quarter 2023 transaction costs deemed significant, settlement of pre-acquisition
share-based payment awards and fair value adjustments to inventory, in each case related to
the acquisition of Abcam (1.50) — (4.90) —
Fourth quarter 2023 impairment charge related to technology-based intangible assets in the
Diagnostics segment and technology-based intangible assets in the Biotechnology segment (0.55) (0.70) — (0.90)
Fourth quarter 2023 gain from the resolution of a litigation contingency in the Life Sciences
segment 0.15 — 0.55 —
Year-over-year core operating profit margin changes for the fourth quarter 2023 (defined
as all year-over-year operating profit margin changes other than the changes identified in
the line items above) (non-GAAP) (4.95) (6.90) (2.80) (4.30)
Three-Month Period Ended December 31, 2023 Operating Profit Margins from Continuing
Operations (GAAP) 20.90 % 23.60 % 12.20 % 28.20 %
Segments
Total Company Biotechnology Life Sciences Diagnostics
Year Ended December 31, 2022 Operating Profit Margins from Continuing Operations
(GAAP) 28.30 % 34.30 % 20.10 % 31.70 %
Full year 2023 impact from operating profit margins of businesses that have been owned for
less than one year or were disposed of during such period and did not qualify as
discontinued operations (0.20) (0.10) (0.45) (0.05)
Fourth quarter 2023 transaction costs deemed significant, settlement of pre-acquisition
share-based payment awards and fair value adjustments to inventory, in each case related to
the acquisition of Abcam (0.40) — (1.30) —
Fourth quarter 2023 impairment charge related to technology-based intangible assets in the
Diagnostics segment and second and fourth quarter 2023 impairment charges related to
technology-based intangible assets and other assets in the Biotechnology segment (0.35) (0.75) — (0.25)
Fourth quarter 2023 gain from the resolution of a litigation contingency in the Life Sciences
segment 0.05 — 0.15 —
Full year 2022 impairments of accounts receivable and inventory as well as accruals for
contractual obligations in Russia 0.15 0.15 0.35 0.05
Year-over-year core operating profit margin changes for full year 2023 (defined as all
year-over-year operating profit margin changes other than the changes identified in the
line items above) (non-GAAP) (5.75) (7.00) (1.95) (6.35)
Year Ended December 31, 2023 Operating Profit Margins from Continuing Operations (GAAP) 21.80 % 26.60 % 16.90 % 25.10 %
Note: The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it determines
that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
DANAHER CORPORATION
Year-Over-Year Core Operating Margin Changes from Continuing Operations
15

-- 17 of 21 --

Three-Month Period Ended Year-over-Year
Change
Year Ended Year-over-Year
Change	December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022
Total Cash Flows from Continuing Operations:
Total cash provided by operating activities from continuing
operations (GAAP) $ 1,591 $ 2,200 $ 6,490 $ 7,613
Total cash used in investing activities from continuing
operations (GAAP) $ (6,017) $ (804) $ (7,048) $ (2,145)
Total cash (used in) provided by financing activities from
continuing operations (GAAP) $ (1,819) $ (906) $ 154 $ (2,570)
Free Cash Flow from Continuing Operations:
Total cash provided by operating activities from continuing
operations (GAAP) $ 1,591 $ 2,200 ~(27.5) % $ 6,490 $ 7,613 ~(15.0) %
Less: payments for additions to property, plant &
equipment (capital expenditures) from continuing
operations (GAAP) (434) (321) (1,383) (1,118)
Plus: proceeds from sales of property, plant & equipment
(capital disposals) from continuing operations (GAAP) 6 — 12 9
Free cash flow from continuing operations (non-GAAP) $ 1,163 $ 1,879 ~(38.0) % $ 5,119 $ 6,504 ~(21.5) %
Operating Cash Flow to Net Earnings Ratio (GAAP)
Total cash provided by operating activities from continuing
operations (GAAP) $ 1,591 $ 2,200 $ 6,490 $ 7,613
Net earnings from continuing operations (GAAP) $ 1,121 $ 2,012 $ 4,221 $ 6,328
Operating cash flow from continuing operations to net
earnings from continuing operations conversion ratio 1.42 1.09 1.54 1.20
Free Cash Flow to Net Earnings Ratio (non-GAAP)
Free cash flow from continuing operations from above
(non-GAAP) $ 1,163 $ 1,879 $ 5,119 $ 6,504
Net earnings from continuing operations (GAAP) $ 1,121 $ 2,012 $ 4,221 $ 6,328
Free cash flow from continuing operations to net earnings
from continuing operations conversion ratio (non-GAAP) 1.04 0.93 1.21 1.03
The Company defines free cash flow as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing operations
(“capital expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”). All amounts presented above reflect only
continuing operations.
DANAHER CORPORATION
Cash Flow from Continuing Operations, Free Cash Flow from Continuing Operations, Operating Cash Flow from Continuing Operations to Net Earnings
from Continuing Operations Ratio and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Conversion Ratio
($ in millions)
16

-- 18 of 21 --

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure,
and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to
investors by offering additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the corresponding GAAP
measure, help our investors:
• with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to
prior and future periods and to our peers;
• with respect to core sales and related non-GAAP sales measures, identify underlying growth trends in our business and compare our sales performance
with prior and future periods and to our peers; and
• with respect to free cash flow from continuing operations and related non-GAAP cash flow measures (the “FCF Measure”), understand Danaher’s ability to
generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other
strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company’s debt service requirements and other non-
discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).
We expect overall demand for the Company’s COVID-19 related products to continue moderating as the pandemic has evolved toward endemic status. We
believe certain demand for the Company’s products that support COVID-19 related vaccines and therapeutics and COVID-19 testing (which includes solutions that
test for COVID-19 and other respiratory illnesses simultaneously) will continue, though that demand will likely be uncertain and will vary from period to period. At
the beginning of 2022, the Company believed that on a relative basis, the level of ongoing demand for products supporting COVID-19 testing would be subject to
more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and therapeutics, due in part to expected COVID-19
case levels, vaccination rates and use of therapies. However, as a result of lower vaccination rates and the spread of less severe variants of the virus, 2022
demand for the Company’s products supporting COVID-19 related vaccines and therapeutics fluctuated and declined more than anticipated at the beginning of the
year. Therefore, beginning with the first quarter of 2023, we have revised the definition of “base business core sales growth” on a basis that not only excludes
revenues related to COVID-19 testing but also excludes revenues from products that support COVID-19 related vaccines and therapeutics. We believe this
adjusted definition of “base business core sales growth” provides more useful information to investors by facilitating period-to-period comparisons of our financial
performance and identifying underlying growth trends in the Company’s business that otherwise may be obscured by fluctuations in demand for COVID-19 related
products.
Management uses the non-GAAP measures referenced above to measure the Company’s operating and financial performance, and uses core sales and non-
GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share from Continuing Operations and the FCF Measure in the Company’s executive
compensation program.
• The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
◦ Amortization of Intangible Assets: We exclude the amortization of acquisition-related intangible assets because the amount and timing of such
charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of
significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price allocated to
intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion
of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held
businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to understand
that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future
periods until such intangible assets have been fully amortized.
◦ Restructuring Charges: We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size,
strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that
result from application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the
ordinary course of our business and we believe are not indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs
to facilitate a more consistent comparison of operating results over time.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
17

-- 19 of 21 --

◦ Other Adjustments: With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share from Continuing
Operations, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may
be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends
and make comparisons of long-term performance difficult. For example, we excluded the first quarter 2022 charge for asset impairments,
accruals for contractual obligations and similar items related to our Russia operations because, even though it is possible we could incur
additional charges in the future, we do not believe these charges are indicative of Danaher’s ongoing operating costs.
• With respect to adjusted average common stock and common equivalent shares outstanding, Danaher’s Mandatory Convertible Preferred Stock (“MCPS”)
Series A converted into Danaher common stock on April 15, 2022 and the MCPS Series B mandatorily converted into Danaher common stock on the
mandatory conversion date of April 17, 2023 (unless converted or redeemed earlier in accordance with the terms of the applicable certificate of
designations). With respect to the calculation of Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we apply the “if
converted” method of share dilution to the MCPS Series A and B in all applicable periods irrespective of whether such preferred shares were dilutive or
anti-dilutive in the period. We believe this presentation provides useful information to investors by helping them understand the net impact on Danaher’s
earnings per share-related measures irrespective of the period.
• With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to “restructuring charges” and
“other adjustments”, we exclude the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued
operations) because the timing, size, number and nature of such transactions can vary significantly from period to period and may obscure underlying
business trends and make comparisons of long-term performance difficult.
• We calculate adjusted EBITDA by adding to operating profit amounts equal to depreciation and amortization and making the other adjustments reflected in
the applicable tables above, which allows us to calculate and disclose such measure by segment. Given Danaher’s diversification, we believe this helps
our investors compare the profitability of our individual segments to peer companies with like business lines.
• With respect to core sales related measures, (1) we exclude the impact of currency translation because it is not under management’s control, is subject to
volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size,
number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure
underlying business trends and make comparisons of long-term performance difficult.
• With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to
demonstrate the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements.
The Company provides forecasted sales only on a non-GAAP basis because of the difficulty in estimating the other components of GAAP revenue, such as
currency translation, acquisitions and divested product lines. Additionally, we do not reconcile forecasted adjusted operating profit margin (or components thereof)
to the comparable GAAP measures because of the difficulty in estimating the other components (in addition to items identified in the prior sentence) such as
investment gains and losses, impairments and separation costs, which would be reflected in any forecasted GAAP operating profit.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
18

-- 20 of 21 --

19

-- 21 of 21 --